The Safety and Efficacy of Telitacicept in the Treatment of Systemic Sclerosis

NCT ID: NCT06546540

Last Updated: 2024-08-09

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE4
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-06-08
• Study Completion Date: 2026-03-30

Brief Summary

Systemic sclerosis (SSc) is a chronic, multisystem autoimmune disease characterized by potentially widespread and progressive skin fibrosis and vascular abnormalities, and may involve the musculoskeletal, gastrointestinal, pulmonary, cardiac, renal, neuromuscular, and urogenital systems. At present, there is no clear and effective drug treatment for the progression of scleroderma skin lesions, and there is a lack of authoritative treatment recommendations. In recent years, research on the treatment of B cells in SSc suggests that targeted B cell therapy has certain safety and effectiveness for SSc patients. Telitacicept is a fully human fusion protein that is a fusion of TACI protein and IgG1 protein. Telitacicept can inhibit the further development and maturation of immature B cells by blocking BLyS. At the same time, Telitacicept can also inhibit the differentiation of mature B cells into plasma cells by blocking APRIL, and affect the secretion of abnormal self reactive plasma cell autoantibodies, better controlling disease activity. The effectiveness and safety of SSc treatment require further research. This study is an evaluator blind, parallel controlled clinical trial that included 20 SSc patients who still had skin progression despite conventional treatment. The patients were divided into two groups, one group included patients who did not improve with conventional treatment for skin lesions, and the other group included patients who received traditional conventional treatment. The main outcome of the study was to evaluate the efficacy and safety of Telitacicept in the treatment of progressive skin lesions in SSc, and the secondary outcome was to evaluate the impact of Telitacicept on lung function, gastrointestinal symptoms, pulmonary arterial hypertension, disease activity, and quality of life in SSc.

Conditions

Systemic Sclerosis

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

Telitacicept

Group Type: EXPERIMENTAL

Telitacicept

Intervention Type: DRUG

160mg，once weekly

Conventional

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

Telitacicept

160mg，once weekly

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Subjects with systemic sclerosis who met the ACR2013 classification criteria for systemic sclerosis and approved this trial

2. Age: 18 years or older

3. Lung function FVC% > 50%

4. Positive for ANA or scleroderma related autoantibodies

5. Patients with disease activity after conventional treatment: new skin involvement or deterioration of two new body areas or skin thickening and deterioration after 6 months of conventional treatment (δMRSS ≥0 points)

6. The dose of the following drugs was stable for at least 6 months before the first use of the study drug: mycophenolate mofetil, cyclophosphamide；First use of study drug precorticosteroids (≤10 mg prednisone/day or equivalent) for at least 30 days

Exclusion Criteria

1. Subjects who did not consent to participate in the clinical trial

2. Subjects with mixed connective tissue disease or overlap syndrome

3. Focal scleroderma

4. Pregnant women, lactating women and men or women who have planned to have children in the last 12 month

5. Allergic reaction: History of allergy to human derived biological products

6. Participants who had participated in any clinical trial within 28 days prior to initial screening/or within a 5-fold half-life of the study compound (whichever is longer)

7. Those who have received live vaccine in the last month

8. B cell-targeted therapies such as rituximab, iparizumab, and beliumab were used within one year

9. Tumor necrosis factor inhibitors and interleukin-receptor blockers were used within one year.

10. Patients who used intravenous gamma globulin (IVIG), prednisone ≧100 mg/d for more than 14 days within one month or underwent plasma exchange surgery

11. Use Chinese medicine for treatment within one month

12. There is active infection (such as herpes zoster, HIV infection, active tuberculosis, etc.) during the screening period

13. There are serious complications such as uncontrolled congestive heart failure, arrhythmias, severe pulmonary hypertension or hypertension, severe gastrointestinal involvement, liver function impairment, active infection, severe diabetes mellitus, atherosclerotic heart disease, malignancy, AIDS, or severe peripheral vascular disease.

14. Patients with severe depression, psychosis or suicidal ideation

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Peking University Third Hospital

OTHER

Sponsor Role: lead

Responsible Party

Mu Rong

professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Peking Third Hospital

Beijing, , China

Site Status: RECRUITING

Countries

China

Central Contacts

Jing Chai

Role: CONTACT

chaijing1008@163.com

86-010-18610089752

Facility Contacts

Jing Chai

Role: primary

86-010-18610089752

Other Identifiers

BYSYDL2021005

Identifier Type: -

Identifier Source: org_study_id